Physician profile
Gary Goldstein
NPI 1952366791
$8,405.41
in general payments reported to CMS, 2019-2025
29 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $543 · 2021: $1,055 · 2022: $830 · 2023: $1,470 · 2024: $2,110 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,065 · Gift: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,064.77 |
| Gift | $488.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,423.20 | 2019-2025 | |
| Braintree Laboratories, INC. | $1,073.99 | 2019-2025 | Sutab, Suflave |
| Fujifilm Healthcare Americas Corporation | $580.56 | 2019-2024 | Fujifilm |
| Nestle Healthcare Nutrition INC. | $548.75 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $533.73 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $530.34 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.28 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $327.02 | 2020-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $249.55 | 2023-2024 | Zeposia |
| Genzyme Corporation | $206.18 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.86 | 2019-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $190.39 | 2025 | Interstim, Inceptiv |
| Gilead Sciences, INC. | $178.97 | 2020-2025 | |
| Pfizer INC. | $176.20 | 2021-2025 | |
| Allergan, INC. | $129.68 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $118.84 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $88.56 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $72.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $61.48 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $52.81 | 2020 | |
| Enterra Medical, INC. | $51.76 | 2025 | |
| Ardelyx, INC. | $48.96 | 2022-2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $48.79 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $25.49 | 2025 | Wegovy |
| Alfasigma USA, INC. | $24.15 | 2020 | |
| Ferring Pharmaceuticals INC. | $19.70 | 2021 | |
| Lucid Diagnostics INC. | $17.66 | 2023 | |
| Evoke Pharma, INC. | $15.54 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $13.57 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.